I cannot provide administration guidelines for drotaverine injection based on the evidence provided, as none of the studies or guidelines address drotaverine's parenteral administration routes, dosages, or injection protocols.
Critical Evidence Gap
The provided evidence contains:
- No FDA drug label for drotaverine injection - The drug label 1 is for "Darvon-N" (propoxyphene napsylate), which is an entirely different medication (an opioid analgesic), not drotaverine
- Research studies using only oral or intramuscular routes - Studies describe intramuscular drotaverine 80 mg 2, 3 and intravenous 40 mg 4, but provide no comprehensive dosing guidelines, dilution protocols, infusion rates, or safety monitoring parameters
- Guidelines about unrelated medications - All guideline evidence [5-6] addresses epinephrine, dopamine, muscle relaxants, and other drugs for anaphylaxis, resuscitation, and emergency care—none mention drotaverine
What the Research Shows (Limited Context)
From the available research on drotaverine:
Intramuscular administration:
- 80 mg IM used for renal colic 2
- 40-80 mg IM repeated hourly (maximum 3 doses) for labor augmentation 3, 7
Intravenous administration:
Common adverse effects noted:
- Transient hypotension, vertigo, nausea 8
- Tachycardia, facial flushing 3
- Generally well-tolerated with no serious adverse events 2, 8, 4
Clinical Reality
Without proper drug labeling or guidelines, I cannot recommend specific injection protocols. The evidence provided is insufficient to establish:
- Proper dilution requirements
- Infusion rates for IV administration
- Maximum daily doses for parenteral routes
- Contraindications specific to injection
- Monitoring parameters during administration
- Pediatric dosing for parenteral routes
- Dose adjustments for renal/hepatic impairment
Consult the actual drotaverine product monograph or local formulary for proper parenteral administration guidelines.